Literature DB >> 21697810

Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease.

Sundararaman Swaminathan1, Sudhir V Shah.   

Abstract

A substantial body of evidence has accumulated linking an increased incidence of cardiovascular disease in patients with acute kidney injury (AKI), chronic kidney disease (CKD), and end-stage renal disease (ESRD). A multitude of novel risk factors related to decreased kidney function might interact with the renal and systemic immune systems involved in renal injury and repair to participate in accelerated atherogenesis (Immune inflammation-Renal injury-Atherosclerosis--the IRA Paradigm). In this review, we will discuss several of these novel risk factors and present the potential for the role of the immune-inflammatory system in accelerated atherosclerosis of kidney disease.

Entities:  

Mesh：

Year:  2011        PMID： 21697810     DOI： 10.1038/ki.2011.178

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  25 in total

1.  Impact of uremia on human adipose tissue phenotype.

Authors:  Karen J Ho; Hui Xue; Christine R Mauro; Binh Nguyen; Peng Yu; Ming Tao; Michael A Seidman; Steven M Brunelli; Charles Keith Ozaki
Journal:  J Surg Res       Date:  2012-09-06       Impact factor: 2.192

2.  Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD.

Authors:  Benjamin Bowe; Yan Xie; Hong Xian; Tingting Li; Ziyad Al-Aly
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-27       Impact factor: 8.237

Review 3.  The three human monocyte subsets: implications for health and disease.

Authors:  Kok Loon Wong; Wei Hseun Yeap; June Jing Yi Tai; Siew Min Ong; Truong Minh Dang; Siew Cheng Wong
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 4.  Atherosclerotic-nephropathy: an updated narrative review.

Authors:  Mariadelina Simeoni; Silvio Borrelli; Carlo Garofalo; Giorgio Fuiano; Ciro Esposito; Alessandro Comi; Michele Provenzano
Journal:  J Nephrol       Date:  2020-04-08       Impact factor: 3.902

Review 5.  Vitamin D and inflammation.

Authors:  Uwe Querfeld
Journal:  Pediatr Nephrol       Date:  2012-12-13       Impact factor: 3.714

6.  Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants.

Authors:  Christina L Fanola; Deirdre Mooney; Andrew J Cowan; Darae Ko; Emily K Sisson; Lori E Henault; Yorghos Tripodis; Elaine M Hylek
Journal:  Am Heart J       Date:  2016-11-04       Impact factor: 4.749

7.  MTHFR, MTR and MTRR polymorphisms and risk of chronic kidney disease in Japanese: cross-sectional data from the J-MICC Study.

Authors:  Asahi Hishida; Rieko Okada; Yin Guang; Mariko Naito; Kenji Wakai; Satoyo Hosono; Kazuyo Nakamura; Tanvir Chowdhury Turin; Sadao Suzuki; Hideshi Niimura; Haruo Mikami; Jun Otonari; Nagato Kuriyama; Sakurako Katsuura; Michiaki Kubo; Hideo Tanaka; Nobuyuki Hamajima
Journal:  Int Urol Nephrol       Date:  2013-04-18       Impact factor: 2.370

Review 8.  Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence.

Authors:  Oscar Leonard; Jonas Spaak; David Goldsmith
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

9.  Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients.

Authors:  Néstor Fontseré; Celia Cardozo; Javier Donate; Alex Soriano; Mercedes Muros; Mercedes Pons; Josep Mensa; Josep M Campistol; Juan F Navarro-González; Francisco Maduell
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

10.  The Development of Benzimidazole-Based Clickable Probes for the Efficient Labeling of Cellular Protein Arginine Deiminases (PADs).

Authors:  Venkatesh V Nemmara; Venkataraman Subramanian; Aaron Muth; Santanu Mondal; Ari J Salinger; Aaron J Maurais; Ronak Tilvawala; Eranthie Weerapana; Paul R Thompson
Journal:  ACS Chem Biol       Date:  2018-02-01       Impact factor: 5.100
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.